Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jimenez-Jimenez

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
JAMA Oncology|May 2, 2024
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid LeukemiaLaura W Dillon, Gege Gui, Niveditha Ravindra, et al.
Blood|December 12, 2025
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trialEverett Meyer, Amandeep Salhotra, Arpita Gandhi, et al.
Bone Marrow Transplantation|November 6, 2024
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Leukemia|May 15, 2024
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysisTrent P Wang, Kwang W Ahn, Mazyar Shadman, et al.
Bone Marrow Transplantation|October 25, 2024
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Bone Marrow Transplantation|November 25, 2025
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemiaRasha W Al-Ali, Gege Gui, Niveditha Ravindra, et al.
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
JAMA Oncology|May 2, 2024
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid LeukemiaLaura W Dillon, Gege Gui, Niveditha Ravindra, et al.
Blood|December 12, 2025
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trialEverett Meyer, Amandeep Salhotra, Arpita Gandhi, et al.
Bone Marrow Transplantation|November 6, 2024
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Leukemia|May 15, 2024
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysisTrent P Wang, Kwang W Ahn, Mazyar Shadman, et al.
Bone Marrow Transplantation|October 25, 2024
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Bone Marrow Transplantation|November 25, 2025
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemiaRasha W Al-Ali, Gege Gui, Niveditha Ravindra, et al.
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Pageof 12